Skip to main content
. 2018 Aug 2;128(10):4525–4542. doi: 10.1172/JCI120401

Figure 2. Low expression of the full-length RNF8 correlates with poor prognosis for breast cancer patients.

Figure 2

(A) Schematic of the different human RNF8 isoforms and the position of the 2 Affymetrix microarray probes 203160_s_at and 203161_s_at included in the KM Plotter application. The 203160_s_at probe recognizes all 4 RNF8 isoforms; the 203161_s_at probe only recognizes the full-length transcript (RNF8-202) that encodes for the full-length functional RNF8 protein containing both its FHA and its RING-finger domains. (B–E) Analysis of relapse-free survival of breast cancer patients using KM Plotter and the median expression level of the RNF8 203161_s_at probe to classify breast cancer cases as expressing either high or low levels of the full-length isoform. The analysis included all breast cancer patients (n = 3,955) and patients with luminal B (n = 1,149), basal-like (n = 618), or HER2+ (n = 251) subtypes. Hazard ratio and 95% confidence intervals of the Cox regression analysis and log-rank P values are shown. NMD, nonsense-mediated decay.